Dr Tan Yew Oo
MBBS(Singapore), FRCP (Canada), FACP (USA), DRACP (Aus), FRCP(Edinburgh), DRCP(Glasgow), FAMS(Medical Oncology), Diplomate of American Board of Internal Medicine, Haematology and Medical Oncology.
“I want patients to feel that I am there to help them begin their cancer journey”
Dr Tan Yew Oo is currently the specialist in medical oncology with Icon SOC Farrer Park, Gleneagles and Mt Alvernia.
He was formerly the Professor of Medicine at the Faculty of Medicine, National University of Singapore (NUS),and Chief of Medicine at National University Hospital (NUH) and Head of the Division of Haematology-Oncology. He was a tenured faculty staff of NUS from 1978 till 1993 and during his tenure, he was instrumental in setting up the specialty of Medical Oncology at National University Hospital. He has been the mentor and teacher to many doctors including many prominent medical oncologists in Singapore.
After he went into private practice, he remained active in medical education and postgraduate training. He had served in the Specialist Training Committee of Medical Oncology, Academy of Medicine/MOH, Singapore, Chairman of the National Committee on Cancer Care, Medical Research Council and consultant to the Health Science Authority.
He was a Director of SingHealth between 2000 till 2006 and currently served as Director of Eastern Health Alliance. He was a member or SMC Review Committee from 2013 to 2014. He currently serves as member of Medishield Life Council since June 2015.
He was the examiner in Master of Medicine (M. Med) and teaches the Family Medicine physicians in Oncology. He remains active in clinical cancer research and he continues to participate in Phase III clinical trials on novel anti-cancer agents.
He published extensively and has been invited to speak at regional and international medical meetings.
Dr Tan’s sub specialist interests include lung, breast and gastrointestinal cancers, lymphomas and liver cancer. He has extensive experience in caring for a wide-range of cancers, both haematologic malignancies and solid tumours and is often consulted for second opinions.